Windtree Therapeutics INC /DE/ Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OTC.Pink
Craig Fraser, CEO of Windtree Therapeutics, recently purchased 5,431 shares of the company's common stock at a price of $0.9099 per share.
OTC.Pink
SVP and Chief Medical Officer of Windtree Therapeutics, Steven Simonson, reports acquisition of Series C Preferred Stock and warrants in a private placement.
OTC.Pink
Form 4: Windtree Therapeutics CEO Acquires Series C Preferred Stock and Warrants in Private Placement
Windtree Therapeutics' CEO, Craig Fraser, acquired 19 shares of Series C Convertible Preferred Stock and 4,011 warrants in a private placement.